Want to see SYRE full AI Analyst Report?
Spyre Therapeutics (SYRE) Ratios
Spyre Therapeutics Ratios
SYRE's free cash flow for Q2 2026 was $-69.88M. For the 2026 fiscal year, SYRE's free cash flow was increased by $0.00 and operating cash flow was $-69.88M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 |
| Quick Ratio | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 |
| Cash Ratio | 1.46 | 1.65 | 5.91 | 2.38 | 0.75 |
| Solvency Ratio | -2.32 | -2.29 | -2.14 | -3.93 | -2.47 |
| Operating Cash Flow Ratio | -2.88 | -2.91 | -3.12 | -5.47 | -2.67 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 715.24M | $ 517.79M | $ 183.69M | $ 41.42M | $ 72.91M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.07 | 0.05 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.09 | 0.06 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.08 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.18 | 1.86 | 1.41 | 1.31 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 1.37 | 1.92 |
| Net Debt to EBITDA | 0.41 | 0.43 | 1.48 | 0.37 | 0.16 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | 0.00% | -14510.61% | -3640.23% | -350.33% |
| EBITDA Margin | 0.00% | 0.00% | -14401.81% | -3555.90% | -341.92% |
| Operating Profit Margin | 0.00% | 0.00% | -27347.97% | -3640.23% | -350.33% |
| Pretax Profit Margin | 0.00% | 0.00% | -38241.08% | -3604.59% | -350.39% |
| Net Profit Margin | 0.00% | 0.00% | -38238.15% | -3598.75% | -351.14% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -38238.15% | -3598.75% | -351.14% |
| Net Income Per EBT | 99.99% | 100.02% | 99.99% | 99.84% | 100.21% |
| EBT Per EBIT | 74.07% | 99.71% | 139.83% | 99.02% | 100.02% |
| Return on Assets (ROA) | -19.95% | -34.19% | -99.10% | -117.81% | -59.86% |
| Return on Equity (ROE) | -21.70% | -40.17% | -184.11% | -166.61% | -78.39% |
| Return on Capital Employed (ROCE) | -29.14% | -37.62% | -78.19% | -150.09% | -73.12% |
| Return on Invested Capital (ROIC) | -29.14% | -37.62% | -78.19% | -148.20% | -72.77% |
| Return on Tangible Assets | -19.95% | -34.19% | -99.10% | -117.81% | -59.86% |
| Earnings Yield | -7.40% | -19.00% | -228.26% | -220.99% | -21.07% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 6.21 | 22.99 |
| Payables Turnover | 19.28 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.35 | 2.24 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.03 | 0.17 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.04 | 0.18 |
| Cash Conversion Cycle | -18.93 | 0.00 | 0.00 | 58.77 | 15.87 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 58.77 | 15.87 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 18.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 58.77 | 15.87 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.64 | -3.35 | -14.49 | -23.77 | -20.43 |
| Free Cash Flow Per Share | -2.64 | -3.35 | -14.49 | -23.78 | -20.64 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -2109.05 | -93.75 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -2109.05 | -93.75 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -17.31 | -10.62 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -112.77 | -34.41 | -2.87 |
| Free Cash Flow Yield | -8.07% | -14.38% | -67.31% | -211.42% | -17.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -16.55 | -7.32 | -0.44 | -0.45 | -4.75 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 167.52 | 16.28 | 16.67 |
| Price-to-Book (P/B) Ratio | 2.93 | 2.11 | 0.81 | 0.75 | 3.72 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -12.40 | -6.96 | -1.49 | -0.47 | -5.75 |
| Price-to-Operating Cash Flow Ratio | -12.40 | -6.96 | -1.49 | -0.47 | -5.81 |
| Price-to-Earnings Growth (PEG) Ratio | 0.44 | 0.08 | -0.01 | 0.71 | 0.14 |
| Enterprise Value Multiple | -9.60 | -4.83 | 0.32 | -0.09 | -4.72 |
| Enterprise Value | 2.01B | 1.01B | -40.47M | 7.69M | 302.20M |
| EV to EBITDA | -9.60 | -4.83 | 0.32 | -0.09 | -4.72 |
| EV to Sales | 0.00 | 0.00 | -45.68 | 3.30 | 16.13 |
| EV to Free Cash Flow | -11.89 | -6.39 | 0.41 | -0.10 | -5.57 |
| EV to Operating Cash Flow | -11.89 | -6.39 | 0.41 | -0.10 | -5.63 |
| Tangible Book Value Per Share | 11.17 | 11.01 | 26.68 | 14.92 | 31.92 |
| Shareholders’ Equity Per Share | 11.17 | 11.01 | 26.68 | 14.92 | 31.92 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | 0.00 | 0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.13 | 0.69 | 7.13 |
| Net Income Per Share | -2.42 | -4.42 | -49.12 | -24.86 | -25.02 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.71 | 1.00 | 2.64 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 101.02 | 25.15 | 3.05 |
| SG&A to Revenue | 0.00 | 0.00 | 45.09 | 12.25 | 1.46 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 28.98 | 3.05 | 0.43 |
| Income Quality | 1.09 | 0.76 | 0.29 | 0.96 | 0.82 |
Currency in USD
